Zelluna Advances Phase 1 ZIMA-101 Trial Following Positive Safety Review From Independent Committee

Zelluna ASA said its IDMC recommended continuing patient enrollment in the Phase 1 ZIMA-101 trial after reviewing safety data from the first patient. This supports the program moving forward in early-stage development, a modest positive signal for trial progression.

Analysis

Zelluna ASA said its IDMC recommended continuing patient enrollment in the Phase 1 ZIMA-101 trial after reviewing safety data from the first patient. This supports the program moving forward in early-stage development, a modest positive signal for trial progression.